Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
C M Rudin, J Holmlund, G F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 8, 2008
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
M M Regan, O Pagani, B Walley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study
S O'Reilly, G F Fleming, S D Barker, et al.
Breast Cancer Research and Treatment
|
January 24, 2002
Expedition inspiration consensus 2001
C C Benz, L Hilakivi-Clarke, S Conzen, et al.
Clinical Pharmacology and Therapeutics
|
March 19, 2014
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies
S Karovic, Y Wen, T G Karrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2000
Phase II evaluation of thalidomide in patients with metastatic breast cancer
S M Baidas, E P Winer, G F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
J F Liu, W T Barry, M Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
M M Regan, B A Walley, P A Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2001
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology
A Recht, S B Edge, L J Solin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
M P Goetz, N A Bagegni, G Batist, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
C M Rudin, J Holmlund, G F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 8, 2008
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
M M Regan, O Pagani, B Walley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study
S O'Reilly, G F Fleming, S D Barker, et al.
Breast Cancer Research and Treatment
|
January 24, 2002
Expedition inspiration consensus 2001
C C Benz, L Hilakivi-Clarke, S Conzen, et al.
Clinical Pharmacology and Therapeutics
|
March 19, 2014
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies
S Karovic, Y Wen, T G Karrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2000
Phase II evaluation of thalidomide in patients with metastatic breast cancer
S M Baidas, E P Winer, G F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
J F Liu, W T Barry, M Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
M M Regan, B A Walley, P A Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2001
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology
A Recht, S B Edge, L J Solin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
M P Goetz, N A Bagegni, G Batist, et al.
Page
of 6